Interim report January-March 2015: Good growth and strengthened income

  • Sales amounted to SEK 162 (119) million, corresponding to an increase of 36 percent in SEK. Sales growth was 19 percent in local currency. The acquisition of Unisense FertiliTech A/S contributed SEK 22 million to sales. Adjusted for this, sales growth amounted to 4 percent in local currency.
  • Operating income before depreciation and amortization (EBITDA) amounted to SEK 54 (36) million, corresponding to a margin of 33 (31) percent. Fluctuations in exchange rates had a positive effect of SEK 12 million on operating income before depreciation and amortization (EBITDA). 
  • Net income amounted to SEK 35 (22) million, which gave earnings per share of SEK 1.61 (1.12).

Gothenburg, April 28, 2015


Thomas Axelsson, CEO

Queries should be addressed to:

Thomas Axelsson, CEO, tel 46 31 721 80 01

Mikael Engblom, CFO, tel 46 31 721 80 14

Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on April 28, 2015 at 08:00 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.


Vitrolife is an international medical device Group. Vitrolife Fertility product area develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes

Vitrolife has approximately 330 employees and the company's products are sold in almost 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The Vitrolife share is listed on NASDAQ OMX Stockholm, Mid Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: Website:


About Us

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets products for assisted reproduction. Vitrolife has about 390 employees and the company’s products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.